Companies › Genmab
9 active drug programs in 68 registered trials: 31 Phase 2, 21 Phase 1, 16 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Epcoritamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma … | Mar 2027 |
| Acasunlimab Bispecific antibody that engages PD-L1 and 4-1BB | CD274, TNFRSF9 | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Jul 2027 |
| Rina-S Topoisomerase 1 inhibitor conjugate (SN-38 payload on anti-TROP-2 antibody) | TOPO1 | Phase 3 | Platinum-resistant Ovarian Cancer; Ovarian Cancer; Endometrial Cancer; Platinum-Sensitive Ovarian Cancer … | Sep 2027 |
| Petosemtamab (MCLA-158) bispecific antibody targeting EGFR and LGR5 | EGFR, CEACAM5, LGR5 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid Tumors | Jan 2028 |
| GEN1042 Bispecific antibody targeting CD40 and 4-1BB (TNFRSF18); DuoBody format | CD40, TNFRSF18 | Phase 1 | Malignant Solid Tumor | Jan 2027 |
| GEN1106 | – | Phase 1 | Solid Tumors | Apr 2029 |
| GEN1119 | – | Phase 1 | Solid Tumours | Jun 2029 |
| GEN3018 Antibody | – | Phase 1 | R/R AML | Oct 2029 |
| GEN1079 | – | Phase 1 | Advanced Solid Tumors | Jan 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06287398 | Epcoritamab | Phase 2 | DLBCL - Diffuse Large B Cell Lymphoma | Oncology | Nov 2026 |
| NCT06672705 | Epcoritamab | Phase 1 | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder | Oncology | Dec 2026 |
| NCT04083599 | GEN1042 | Phase 1 | Malignant Solid Tumor | Oncology | Jan 2027 |
| NCT06723457 | Epcoritamab | Phase 2 | Recurrent B-Cell Non-Hodgkin Lymphoma | Oncology | Feb 2027 |
| NCT05451810 | Epcoritamab | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Mar 2027 |
| NCT06510491 | Epcoritamab | Phase 2 | Waldenstrom Macroglobulinemia | Oncology | Apr 2027 |
| NCT05578976 | Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2027 |
| NCT07108998 | Epcoritamab | Phase 2 | CLL/SLL | Oncology | Jul 2027 |
| NCT06676033 | Epcoritamab | Phase 1 | Leukemia, Chronic Lymphocytic | Oncology | Jul 2027 |
| NCT06635824 | Acasunlimab | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Oncology | Jul 2027 |
| NCT06112847 | Epcoritamab | Phase 2 | Follicular Lymphoma | Oncology | Aug 2027 |
| NCT06057038 | GEN1042 | Phase 1 | Malignant Solid Tumor | Oncology | Aug 2027 |
| NCT06536049 | Epcoritamab | Phase 1 | Recurrent Diffuse Large B-Cell Lymphoma | Oncology | Aug 2027 |
| NCT07604766 | Rina-S | Phase 3 | Platinum-resistant Ovarian Cancer | Oncology | Sep 2027 |
| NCT04542824 | Epcoritamab | Phase 1 | Diffuse Large B Cell Lymphoma | Oncology | Sep 2027 |
| NCT07451652 | Epcoritamab | Phase 2 | Relapsed/Refractory Diffuse Large B Cell Lymphoma | Oncology | Sep 2027 |
| NCT04663347 | Epcoritamab | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Sep 2027 |
| NCT06619236 | Rina-S | Phase 3 | Platinum-resistant Ovarian Cancer | Oncology | Oct 2027 |
| NCT05201248 | Epcoritamab | Phase 1 | B-Cell Non-Hodgkin Lymphoma | Oncology | Oct 2027 |
| NCT06458439 | Epcoritamab | Phase 2 | Lymphoma, Non-Hodgkin | Oncology | Oct 2027 |
| NCT07288177 | Rina-S | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | Oncology | Nov 2027 |
| NCT05852717 | Epcoritamab | Phase 2 | Large Cell Lymphoma, Diffuse | Oncology | Nov 2027 |
| NCT04623541 | Epcoritamab | Phase 1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | Oncology | Dec 2027 |
| NCT06931652 | Epcoritamab | Phase 2 | Primary CNS Lymphoma (PCNSL) | Oncology | Jan 2028 |
| NCT06525220 | Petosemtamab (MCLA-158) | Phase 3 | Head and Neck Squamous Cell Carcinoma | Oncology | Jan 2028 |
| NCT05783609 | Epcoritamab | Phase 2 | Follicular Lymphoma | Oncology | Feb 2028 |
| NCT06496178 | Petosemtamab (MCLA-158) | Phase 3 | Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2028 |
| NCT06508658 | Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Mar 2028 |
| NCT04628494 | Epcoritamab | Phase 3 | Diffuse Large B-cell Lymphoma | Oncology | Apr 2028 |
| NCT06510361 | Epcoritamab | Phase 2 | Lymphoma | Oncology | May 2028 |
| NCT06414148 | Epcoritamab | Phase 2 | Relapsed/Refractory Large B-cell Lymphoma | Oncology | May 2028 |
| NCT03526835 | Petosemtamab (MCLA-158) | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | May 2028 |
| NCT07226752 | Epcoritamab | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2028 |
| NCT06905509 | Epcoritamab | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | Oncology | Jul 2028 |
| NCT06045247 | Epcoritamab | Phase 2 | Large B-cell Lymphoma | Oncology | Jul 2028 |
| NCT07082868 | Epcoritamab | Phase 1 | Primary Central Nervous System Lymphoma (PCNSL) | Oncology | Aug 2028 |
| NCT06447376 | Epcoritamab | Phase 1 | Non-Hodgkin Lymphoma | Oncology | Sep 2028 |
| NCT07539311 | Rina-S | Phase 2 | Gastrointestinal Cancers | Oncology | Sep 2028 |
| NCT06811272 | Epcoritamab | Phase 2 | Relapsed Large B-cell Lymphoma | Oncology | Oct 2028 |
| NCT07883135 | Epcoritamab | Phase 2 | Aggressive B-cell Non-Hodgkin Lymphoma (aNHL) | Oncology | Oct 2028 |
| NCT07225270 | Rina-S | Phase 3 | Ovarian Cancer | Oncology | Oct 2028 |
| NCT06796998 | Epcoritamab | Phase 2 | Marginal Zone Lymphoma | Oncology | Oct 2028 |
| NCT05206357 | Epcoritamab | Phase 1 | Non-hodgkin Lymphoma | Oncology | Nov 2028 |
| NCT05579366 | Rina-S | Phase 1 | High Grade Epithelial Ovarian Cancer | Oncology | Dec 2028 |
| NCT03625037 | Epcoritamab | Phase 1 | DLBCL | Oncology | Jan 2029 |
| NCT05791409 | Epcoritamab | Phase 1 | CLL/SLL | Oncology | Mar 2029 |
| NCT07775287 | Petosemtamab (MCLA-158) | Phase 3 | Colorectal Cancer | Oncology | Mar 2029 |
| NCT07416123 | GEN1106 | Phase 1 | Solid Tumors | Oncology | Apr 2029 |
| NCT05848765 | Epcoritamab | Phase 2 | Relapsed Follicular Lymphoma | Oncology | May 2029 |
| NCT07218510 | Epcoritamab | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Jun 2029 |
| NCT07695831 | GEN1119 | Phase 1 | Solid Tumours | Oncology | Jun 2029 |
| NCT07702032 | Petosemtamab (MCLA-158) | Phase 3 | Left-sided Colorectal Cancer | Oncology | Jul 2029 |
| NCT07166094 | Rina-S | Phase 3 | Endometrial Cancer | Oncology | Aug 2029 |
| NCT07365306 | Epcoritamab | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Oncology | Oct 2029 |
| NCT07384715 | GEN3018 | Phase 1 | R/R AML | Oncology | Oct 2029 |
| NCT07564141 | Rina-S | Phase 3 | Platinum-Sensitive Ovarian Cancer | Oncology | Dec 2029 |
| NCT05409066 | Epcoritamab | Phase 3 | Follicular Lymphoma (FL) | Oncology | Dec 2029 |
| NCT06238648 | Epcoritamab | Phase 2 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Oncology | Dec 2029 |
| NCT06563596 | Epcoritamab | Phase 2 | Follicular Lymphoma | Oncology | Mar 2030 |
| NCT07197307 | Epcoritamab | Phase 2 | Aggressive Diffuse Large B-cell Lymphoma | Oncology | Apr 2030 |
The 60 nearest readouts of 68 trials; the rest in the app.
Cash and short-term investments of $1.7bn on 2025-12-31; operating cash flow positive
TOPO1 (1) MS4A1 (1) CD3E (1) CD3G (1) CD3D (1) CD40 (1) TNFRSF18 (1) EGFR (1) CEACAM5 (1) LGR5 (1) CD274 (1) TNFRSF9 (1)
Roche Johnson & Johnson (Janssen) Amgen Regeneron Pharmaceuticals AbbVie AstraZeneca Tiziana Life Sciences Pfizer Biocad Novartis
Immunocore Exelixis Shanghai JMT-Bio LaNova Medicines Prestige Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.